Magnetic Resonance Imaging-Guided Cryoablation of Prostate Cancer Lymph Node Metastasis.

Autor:	Mushtaq A; Department of Radiology and Imaging Sciences, Emory University Hospital, Atlanta, Georgia. Electronic address: aliza.mushtaq.21@gmail.com., Mynderse L; Department of Radiology, Mayo Clinic, Rochester, Minnesota; Department of Urology, Mayo Clinic, Rochester, Minnesota., Thompson S; Department of Radiology, Mayo Clinic, Rochester, Minnesota., Adamo D; Department of Radiology, Mayo Clinic, Rochester, Minnesota., Lomas D; Department of Urology, Mayo Clinic, Rochester, Minnesota., Favazza C; Department of Medical Physics, Mayo Clinic, Rochester, Minnesota., Lu A; Department of Medical Physics, Mayo Clinic, Rochester, Minnesota., Kwon E; Department of Urology, Mayo Clinic, Rochester, Minnesota., Woodrum D; Department of Radiology, Mayo Clinic, Rochester, Minnesota.
Jazyk:	angličtina
Zdroj:	Journal of vascular and interventional radiology : JVIR [J Vasc Interv Radiol] 2024 Oct; Vol. 35 (10), pp. 1474-1480. Date of Electronic Publication: 2024 Jun 22.
DOI:	10.1016/j.jvir.2024.06.015
Abstrakt:	Purpose: To evaluate the safety and effectiveness of magnetic resonance (MR) imaging-guided cryoablation of prostate cancer metastatic lymph nodes (LNs). Materials and Methods: Fifty-two patients with prostate cancer who underwent MR imaging-guided LN ablation from September 2013 to June 2022 were retrospectively reviewed. Of these, 6 patients were excluded because adequate ablation margins (3-5 mm) could not be achieved secondary to adjacent structures. The remaining 46 patients (mean age, 70 years [SD ± 7]) underwent 55 MR imaging-guided cryoablation procedures of metastatic LNs (25 in the pelvic sidewall, 20 within the pelvic region, and 10 in the abdomen) with procedural intent of complete ablation. Locoregional tumor control (ie, technical success in the target LN) was evaluated on initial follow-up positron emission tomography (PET) scans at a mean of 4 months (SD ± 2). Preablation and postablation prostate-specific antigen (PSA) levels were recorded. Imaging follow-up continued until a median of 27.5 months (range: 3-108 months). Results: Ninety-five percent (52/55) of treated LNs demonstrated no considerable activity on PET scans at initial follow-up at 4 months (SD ± 2). PSA decreased to an undetectable level of <0.1 ng/mL after cryoablation in 14 of 46 (30.4%) patients with corresponding lack of activity in 13 of 46 (28.2%) patients on continued PET imaging follow-up. Only 6 of 55 (10.9%) patients had transient adverse events, which all resolved with no long-term sequelae. Conclusions: MR imaging-guided percutaneous cryoablation of metastatic LNs is a safe and technically effective technique for treating metastatic prostate cancer in LNs. (Copyright © 2024 SIR. Published by Elsevier Inc. All rights reserved.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu